25151-81-9

Basic information

• Product Name: prostanoic acid
• Synonyms: prostanoic acid;(1S,2S)-2-Octylcyclopentaneheptanoic acid;9,15-Dideoxyprostanoic acid;Prostan-1-oic acid
• CAS NO: 25151-81-9
• Molecular Formula: C5H8(C8H17)C6H12COOH
• Molecular Weight: 310.51
• Mol File: 25151-81-9.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: prostanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: prostanoic acid(25151-81-9)
• EPA Substance Registry System: prostanoic acid(25151-81-9)

Safety Data

• Hazardous Substances Data: 25151-81-9(Hazardous Substances Data)

Usage

Description

Prostanoic acid, also known as prostaglandin, is a group of naturally occurring lipid compounds derived from unsaturated fatty acids. They are characterized by the presence of a cyclopentane ring and a carboxylic acid group. Prostanoic acid plays a crucial role in various physiological processes, including inflammation, blood clotting, and the regulation of blood flow.

Uses

Used in Human Life Extension Therapy:
Prostanoic acid is used as a therapeutic agent for human life extension therapy. It is involved in the molecular, cellular, and subcellular management of biochemical requirements of mitochondria and other organelle processes associated with the advent of disease and/or aging. By modulating these processes, prostanoic acid contributes to the overall health and longevity of an individual.

Upstream product

• 61549-96-0 methyl prostanoate 
• 58986-86-0 prost-5-enoic acid 
• 10067-33-1 (S)-(-)-p-mentha-1,8⁽¹⁰⁾-dien-9-ol 
• 106026-62-4 (1R,2R)-1-3-<(3ξ)-3-hydroxybutyl>-2-hydroxymethylcyclopentane 
• 106026-66-8 (1R,2S)-1-(3,3-ethylenedioxybutyl)-2-hydroxymethylcyclopentane 
• 106026-63-5 (1R,2R)-1-3-(3-oxobutyl)-2-carboxycyclopentane 
• 106026-69-1 (1R,2S)-1-(3,3-ethylenedioxybutyl)-2-octylcyclopentane 
• 10067-31-9 (S)-2-(4-methylcyclohex-3-en-1-yl)allyl acetate 
• 106026-64-6 (1R,2R)-1-3-(3-oxobutyl)-2-methoxycarbonylcyclopentane 
• 106026-67-9 (1R,2S)-1-(3,3-ethylenedioxybutyl)-2-formylcyclopentane 
• 106026-58-8 (3S)-3-(3-acetoxy-1-propene-2-yl)-6-oxo-1-heptanal 
• 89822-43-5 (3S,6ξ)-3-(3-acetoxy-1-propene-2-yl)-6-hydroxy-1-heptanal 
• 89837-49-0 (S)-(-)-9-acetoxy-1⁽²⁾-epoxy-p-menth-8⁽¹⁰⁾-ene 
• 89822-05-9 Acetic acid 2-((S)-3,4-dihydroxy-4-methyl-cyclohexyl)-allyl ester 

Relevant articles and documents

Prostaglandins E and anti-ulcers containing same

The novel 13,14-dihydro-15-keto prostaglandins E of the invention have remarkable preventive effects against ulcers. Further, the novel 13,14-dihydro-15-keto-prostaglandins E of the invention have an advantage that they have none of side effects which prostaglandin E intrinsically has, or can remarakably reduce such effects of the prostaglandin E. Therefore, the novel 13,14-dihydro-15-keto prostaglandins E of the invention are effective for animal and human use for treatment and prevention of ulcers, such as duodenal ulcer and gastric ulcer.

Novel prostaglandins

This disclosure describes novel 15-hydroxy prostanoic acid derivatives having anti-ulcer, bronchodilator, and hypotensive activity.